Nuformix plc (LSE:NFX), a pharmaceutical development company focusing on fibrosis and oncology through drug repurposing, announced on Monday that it has submitted a draft application for Orphan Drug Designation (ODD) to the European Medicines Agency (EMA) for its lead asset, NXP002.
This drug is being developed as an inhaled treatment for Idiopathic Pulmonary Fibrosis (IPF), a severe respiratory condition with limited therapeutic options.
The draft submission precedes a pre-submission meeting with the EMA, scheduled for later in January 2025. Following the meeting, the company anticipates submitting the formal ODD application, with updates on the review timeline and decision expected shortly thereafter.
In parallel, Nuformix is actively engaged in discussions with potential partners to secure an out-licence or option agreement for NXP002, underscoring its commercial potential.
Nuformix specialises in developing novel drug forms with improved properties to address unmet medical needs. Its pipeline of preclinical assets offers significant value and early licensing opportunities, leveraging innovative approaches to drug repurposing.
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
Syndax Pharmaceuticals grants share purchase inducement awards to six new employees
Hippo Pharmacy launches fast, free delivery on orders over USD150
Polarean Imaging expands reach with Taiwanese distribution deal
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
CHMP recommends EU approval of Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan
Renalys Pharma completes patient enrolment for Phase III clinical trial of sparsentan
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
Roche's blood test measuring Lp(a) in molar units receives US FDA 510(k) approval
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Amgen's BLINCYTO (blinatumomab) monotherapy approved in Europe
HeartBeam submits FDA 510(k) application for groundbreaking 12-lead ECG synthesis software
FDA grants Vicore Pharma Fast Track Designation for buloxibutid in idiopathic pulmonary fibrosis
FDA accepts Saol Therapeutics' SL1009 New Drug Application for Priority Review